World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
46954
World Ranking
8783
National Ranking
4527

Bradley J. Monk publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Bradley J. Monk sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 819 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Bradley J. Monk D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Bradley J. Monk sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Bradley J. Monk is affiliated with the University of Arizona in the United States. Their research focuses primarily on medicine, with a strong emphasis on oncology, reproductive medicine, and obstetrics and gynecology. Additional subfields of study include pulmonary and respiratory medicine as well as surgery.

The scientist's main research topics include:

  • Ovarian cancer diagnosis and treatment
  • Endometrial and cervical cancer treatments
  • PARP inhibition in cancer therapy
  • Cancer immunotherapy and biomarkers
  • Cervical cancer and HPV research
  • Cancer genomics and diagnostics
  • Lung cancer treatments and mutations

Bradley J. Monk has contributed to a variety of journals and publication venues, with the most frequent being:

  • Gynecologic Oncology
  • Journal of Clinical Oncology
  • International Journal of Gynecological Cancer
  • Annals of Oncology
  • The Lancet Oncology

Their recent notable papers include:

  • Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer, 2021, New England Journal of Medicine
  • Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer, 2023, New England Journal of Medicine
  • Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study, 2021, The Lancet Oncology
  • Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study, 2021, The Lancet Oncology
  • A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45), 2022, Journal of Clinical Oncology

Throughout their career, the scientist has frequently collaborated with several colleagues, including:

  • Robert L. Coleman
  • David M. O'Malley
  • Krishnansu S. Tewari
  • Kathleen N. Moore
  • Domenica Lorusso

Best Publications

  • Incorporation of bevacizumab in the primary treatment of ovarian cancer

    Robert A. Burger;Mark F. Brady;Michael A. Bookman;Gini F. Fleming

  • Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Mansoor R. Mirza;Bradley J. Monk;Jørn Herrstedt;Amit M. Oza

  • Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Antonio González-Martín;Bhavana Pothuri;Ignace Vergote;René DePont Christensen

  • Improved Survival with Bevacizumab in Advanced Cervical Cancer

    Krishnansu S. Tewari;Michael W. Sill;Harry J. Long;Richard T. Penson

  • Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Antonio González-Martín;Bhavana Pothuri;Ignace Vergote;René De Pont Christensen

  • Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

    Robert A. Burger;Michael W. Sill;Bradley J. Monk;Benjamin E. Greer

  • Carcinogenic human papillomavirus infection.

    Mark Schiffman;John Doorbar;Nicolas Wentzensen;Silvia de Sanjosé

  • Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer

    John B. Welsh;Patrick P. Zarrinkar;Lisa M. Sapinoso;Suzanne G. Kern

  • Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

    Bradley J. Monk;Michael W. Sill;D. Scott McMeekin;David E. Cohn

  • Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

    Nicoletta Colombo;Coraline Dubot;Domenica Lorusso;M Valeria Caceres

  • Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

    Maurie Markman;P.Y. Liu;Sharon Wilczynski;Bradley Monk

  • Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

    Krishnansu S. Tewari;Michael W. Sill;Richard T. Penson;Helen Huang

  • Latest research and treatment of advanced-stage epithelial ovarian cancer

    Robert L. Coleman;Bradley J. Monk;Anil K. Sood;Thomas J. Herzog

  • Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

    Bradley J. Monk;Thomas J. Herzog;Stanley B. Kaye;Carolyn N. Krasner

  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Kathleen N Moore;Angeles Alvarez Secord;Melissa A Geller;David Scott Miller

  • Adhesions after extensive gynecologic surgery: Clinical significance, etiology, and prevention * ** *

    Bradley J. Monk;Michael L. Berman;F.J. Montz

  • Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

    Bradley J. Monk;Michael W. Sill;Robert A. Burger;Heidi J. Gray

  • Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

    John K. Chan;Mark F. Brady;Richard T. Penson;Helen Huang

  • Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

    Andreas Du Bois;Anne Floquet;Jae Weon Kim;Jae Weon Kim;Joern Rau

  • Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer

    Krishnansu S. Tewari;Robert A. Burger;Danielle Enserro;Barbara M. Norquist

Frequent Co-Authors

Thomas J. Herzog
Thomas J. Herzog University of Cincinnati
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center
David M. O'Malley
David M. O'Malley The Ohio State University
Kathleen N. Moore
Kathleen N. Moore University of Oklahoma Health Sciences Center
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Michael J. Birrer
Michael J. Birrer University of Arkansas for Medical Sciences
Robert S. Mannel
Robert S. Mannel University of Oklahoma Health Sciences Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA doesn’t always mean following the traditional route to become a doctor. Many students consider related fields that offer rewarding, impactful opportunities with flexible online learning options. Programs such as adn programs (Associate Degree in Nursing) provide a practical pathway to becoming a registered nurse in less time than a full bachelor’s degree.

Those interested in administrative roles can benefit from accelerated healthcare programs offered online, helping you enter the workforce quickly. Additionally, online medical coding classes with financial aid can open doors to essential roles in the growing field of healthcare information management, with minimal upfront costs.

For those seeking less competitive entry requirements, there are nursing schools that don't require teas or hesi exams, reducing barriers to admission and attracting a wider range of applicants. These options highlight how students can pursue diverse, valuable healthcare careers through accessible and flexible education paths beyond medical school.

Best Scientists Citing Bradley J. Monk

Trending Scientists